Benefits of hepatitis C screening;Interet du depistage de l'hepatite C

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 1 BIS, 1997, Pages

  Trépo, Christian ^a  

^a HÔTEL DIEU   (France)

Author keywords

chronic hepatitis; cost effectiveness; hepatitis C virus; interferon; screening

Indexed keywords

INTERFERON;

CHRONIC HEPATITIS; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEPATITIS C; HEPATITIS C VIRUS; MEDICOLEGAL ASPECT; SCREENING TEST;

EID: 0031003975     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Power JP, Lawlor E, Davidson F, Homes EC, Yap PL, Simmonds P. Hepatitis C viremia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 1994;344:1166-7.
2. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus screened intravenous immunoglobulins. Transfusion 1994;34:86-7.
3. Allander T, Gruber A, Naghavi M, Bcyene A, Söderström T, Björkholm M, et al. Frequent patient-to-patient transmission of hepatitis C virus in an haematology ward. Lancet 1995;345:603-7.
4. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
5. Vogel W, Umlauft F, Grazaidei J, Datz C, Grünewald K. Quantification of hepatitis C treated with high dose alpha interferon (abstract). Hepatology 1994;20:411A.
6. Alberti A, Chemello L, Belussi F, Pontisso P, Tisminetzki S, Gerotto M, et al. Outcome of acute hepatitis C and role of alpha interferon therapy. In: Nishioka K, Suzuki H, Mishiro S, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer Verlag, 1994:604-6.
7. Poynard T, Bedossa P, Mathurin P, Naveau S, Delfraissy JF, Lemaigre G, et al. Efficacy of a long term recombinant interferon alfa in patients with chronic hepatitis C. A clinical, biological, histological and immunohistological study Gastroenterol Clin Biol 1991;15:615-9.
8. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa W, Takano S, et al. Randomized double-blind placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non A, non-B hepatitis. Dig Dis Sci 1991;36:1217-22.
9. Andrieu J, Barny S, Colardelle P, Maisonneuvc P, Giraud V, Robin E, et al. Prévalence et facteurs de risque de l'infection par le virus de l'hépatite C dans une population hospitalisée en gastroentérologie. Rôle des biopsies perendoscopiques. Gastroenterol Clin Biol 1995;19:340-5.
10. Réseau National de Santé Publique. Action concertéc hépatite C. 1995.
11. Carrao G, Carle F, Lepore AR, Zepponi E, Galatola G, Di Orio F. Interaction between alcohol consumption and positivity for antibodies to hepatitis C virus on the risk of liver cirrhosis: a case control study. Eur J Epidemiol 1992;8:634-9.
12. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
13. Hoofnagle JH, Lau D. Chronic viral hepatitis-benefits of current therapies. N Engl J Med 1996;334:1470-1.
14. Jullien AM. Transfusion et hépatite C. Pathol Biol 1995;43:725-34.